Monoclonal antibodies inhibiting cytokines (also referred to as biologic therapy or biologicals) and specifically anti-tumor necrosis factor (TNF)-α have first proved efficacy in the early 90s in the treatment of patients with methotrexate-resistant rheumatoid arthritis [65]. Here, TNF is linked to rheumatoid arthritis.